



## **PRESS RELEASE**

Lelystad, the Netherlands, 19 April 2011

### **Fornix announces interim dividend April 2011**

- **Interim dividend in relation to net proceeds of the sale of Laprolan B.V. (Laprolan) has now been established at € 0.96 per ordinary share**
- **Ex-dividend listing on 21 April, declaration of dividend on 29 April 2011**

**Fornix BioSciences N.V. (NYSE Euronext: AFORBI) is announcing that the interim dividend, to be fully paid in cash, in relation to the net proceeds of the sale of Laprolan, has been established at € 0.96 per ordinary share, with a nominal value of € 0.15. The sale of Laprolan to Rochester Medical Corporation was approved during the Extraordinary General Meeting of Shareholders held on 30 March 2011. The transaction was completed on 7 April 2011 by the transfer of the entire issued share capital of Laprolan against payment of the agreed consideration payable.**

With reference to the previous press releases of 15 February 2011 and 30 March 2011, as well as the explanation given thereto during the Extraordinary General Meeting of Shareholders, held on 30 March 2011, the net proceeds of the sale of Laprolan is defined as the agreed purchase price less costs directly related to the transaction (consisting of transaction costs, a tax liability in relation to article 15ai of the Corporate Income Tax Act and an obligatory reservation for the benefit of the purchaser) and amounts to € 0.96 per ordinary share, on the basis of 8,047,688 outstanding shares less 316,000 shares held by Fornix.

The following schedule applies to the payment of this interim dividend on the ordinary shares:

19 April 2011	Fixing of the interim dividend
21 April 2011	Ex-dividend listing
27 April 2011	Record date for dividend
29 April 2011	Declaration of dividend

Holders of ordinary shares will receive the interim dividend in cash, less 15% dividend withholding tax, through the intermediary of the organisations affiliated with Euroclear Nederland, where the ordinary shares in question will be administered on the registration date, at their expense and after close of business. The dividend will be paid by Kempen & Co N.V. in Amsterdam.

**END OF PRESS RELEASE**

---

**For additional information, please contact: Fornix BioSciences N.V.  
C.L. Bergman, CEO  
Tel. +31 (0) 320) 26 77 99  
[www.fornix.nl](http://www.fornix.nl)**

**Profile of Fornix BioSciences N.V.**

**Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which was engaged in the distribution of medical aids and medical and nursing consumables.**

**With the transfer of all of its shares in Laprolan B.V. to Rochester Medical Corporation, Fornix BioSciences N.V. has divested all of its activities.**